These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1751125)

  • 1. Glomerulopressin in end-stage renal disease. Effect of hemodialysis.
    Zhou XJ; Vaziri ND; Kaupke CJ
    ASAIO Trans; 1991; 37(3):M235-6. PubMed ID: 1751125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of chronic renal failure and hemodialysis on plasma glomerulopressin.
    Zhou XJ; Vaziri ND; Kaupke CJ
    Int J Artif Organs; 1993 Apr; 16(4):180-4. PubMed ID: 8325694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis.
    Luedike P; Rammos C; Pohl J; Heisler M; Totzeck M; Kleophas W; Hetzel GR; Kelm M; Hendgen-Cotta U; Rassaf T
    PLoS One; 2015; 10(10):e0140215. PubMed ID: 26485680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of residual glomerular filtration rate and renal Kt/Vurea from creatinine clearance in end-stage renal disease patients. The Netherlands Cooperative Study on the Adequacy of Dialysis.
    Korevaar JC; Jansen MA; Dekker FW; Boeschoten EW; Krediet RT
    Adv Perit Dial; 1999; 15():132-7. PubMed ID: 10682088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.
    Satirapoj B; Supasyndh O; Phantana-Angkul P; Ruangkanchanasetr P; Nata N; Chaiprasert A; Kanjanakul I; Choovichian P
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S87-93. PubMed ID: 22043573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations.
    Gerritsen KG; Abrahams AC; Peters HP; Nguyen TQ; Koeners MP; den Hoedt CH; Dendooven A; van den Dorpel MA; Blankestijn PJ; Wetzels JF; Joles JA; Goldschmeding R; Kok RJ
    Am J Kidney Dis; 2012 May; 59(5):619-27. PubMed ID: 22342213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
    Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
    Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
    Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
    Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis.
    Handelman GJ; Walter MF; Adhikarla R; Gross J; Dallal GE; Levin NW; Blumberg JB
    Kidney Int; 2001 May; 59(5):1960-6. PubMed ID: 11318969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced glomerulopressin production and glomerular filtration rate by amino acid infusion in normal humans.
    Maggiora EM; Silberstein C; Arany E; Salvidea JC; del Castillo E; Uranga J
    Proc Soc Exp Biol Med; 1991 Feb; 196(2):170-4. PubMed ID: 1990407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis.
    Gheuens E; Daelemans R; Mesens S
    Invest Radiol; 2014 Aug; 49(8):505-8. PubMed ID: 24619209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
    El-Assal MI; Helmy SA
    Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function and serum albumin at the start of dialysis in 514 Chinese ESRD in-patients.
    Liu H; Peng Y; Liu F; Xiao H; Chen X; Huang A; Liu Y
    Ren Fail; 2008; 30(7):685-90. PubMed ID: 18704816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homocysteine in renal failure.
    Hultberg B; Andersson A; Sterner G
    Clin Nephrol; 1993 Oct; 40(4):230-5. PubMed ID: 8261681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients.
    El-Shehaby AM; El-Khatib MM; Battah AA; Roshdy AR
    Scand J Clin Lab Invest; 2010 Oct; 70(6):421-7. PubMed ID: 20645679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic ionized magnesium concentration in end-stage renal disease. Effect of hemodialysis.
    Kaupke CJ; Zhou XJ; Vaziri ND
    ASAIO J; 1993; 39(3):M614-7. PubMed ID: 8268611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebound kinetics of beta2-microglobulin after hemodialysis.
    Leypoldt JK; Cheung AK; Deeter RB
    Kidney Int; 1999 Oct; 56(4):1571-7. PubMed ID: 10504510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual renal function and mortality risk in hemodialysis patients.
    Shemin D; Bostom AG; Laliberty P; Dworkin LD
    Am J Kidney Dis; 2001 Jul; 38(1):85-90. PubMed ID: 11431186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.